Provided is a method of optimizing animal colostrum for human consumption by removing allergenic components and combining one or more immune factors to enable the composition to target the mucosal barriers, thereby enhancing mucosal integrity and increasing immune support. The composition is purified to remove one or more of lactose, casein proteins, fats, and/or oils, thereby creating a product that is devoid of allergenic components. The composition may be combined with a prebiotic, and/or natural sweeteners, additional vitamins, herbs, and/or minerals, and flavoring ingredients. The resulting product forms an instantly dissolvable powder that can be distributed in single serve packets, aerosolized spray, and/or in a chewable form. Furthermore, the composition can be used as an ingredient in food and beverages, in infant formula, in medical foods, or in over-the-counter drugs. Also provided is a method of manufacturing the bioactive composition.

This application is directed to systems and methods of creating sterilized powdered food product. Specific examples regarding breast milk are described whereby the milk is powderized and placed into a vat before it is passed along to a sterilization chamber in which it is fluidized and sterilized by UV-C light. Once powdered food product has been sufficiently sterilized, it can be loaded into syringes for distribution. Embodiments of the inventive subject matter are designed to maintain nutritional value of the powdered food at levels that were not previously possible, opening new opportunities for storing and distribution of, e.g., donor breast milk.

The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level as well as modulation thereof, particularly disorders and conditions wherein therapeutic strategy is based on the increasing of the BDNF concentration in blood.

The PRP complex is postulated to be used for nutrition of adults, young children/babies and infants to promote and preserve the proper development and function of both immune and nervous system. PRPs may be used for supplementation of modified milk and infant milk formulae to make it closer to breast milk.

The present invention relates to a nutritional composition comprising at least one human milk oligosaccharide comprising 3 sialyllactose (3-SL), lacto-N-tetraose (LNT), core-HMOs and any combination thereof for improving improving total night sleep duration in a subject.

Gender specific synthetic nutritional compositions for infants up to 1 month of age contain a caseins content adapted based on that found in human milk produced for an infant of the same gender and age. The compositions can be used in a method of treating, protecting or mitigating sub-optimal growth and development of an infant up to 1 month of age.

Disclosed are spray-dried powders containing a mixture of structurally distinct human milk oligosaccharides, methods for the production of said spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing said spray-dried powder.

Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3-SL and/or 6-SL, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.

The present invention relates to a method for treating raw human milk to produce treated human milk having undetectable levels of bacteria. The milk is skimmed to produce skim human milk then subjected to microfiltration to yield a filtrate which has undetectable levels of bacteria, including Bacillus cereus. The resultant human milk can be further processed, used and/or sold.

The present invention relates to a method for treating raw human milk to produce treated human milk having undetectable levels of bacteria. The milk is skimmed to produce skim human milk then subjected to microfiltration to yield a filtrate which has undetectable levels of bacteria, including Bacillus cereus. The resultant human milk can be further processed, used and/or sold.

Methods and apparatus for improving expressed human milk (EHM0 shelf-life as well as maintaining or improving EHM taste and smell comprising the utilization of specific lipase inhibitors and antibodies.